Pharmacovigilance Risk Assessment Committee (PRAC) Meeting Highlights

Notice type: 3rd Party Publications

Date: 12/07/2019

 

Background Information Or Related Documents:

The Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring safety issues for human medicines. Its recommendations are considered by the Committee for Medicinal Products for Human Use (CHMP) when it adopts opinions for centrally authorised medicines and referral procedures and by the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) when it provides a recommendation on the use of a medicine in Member States. 

Pharmacovigilance Risk Assessment Committee (PRAC) Meeting Highlights 2-5 September 2019

Pharmacovigilance Risk Assessment Committee (PRAC) Meeting Highlights 8-11 July 2019

Pharmacovigilance Risk Assessment Committee (PRAC) Meeting Highlights 11-14 June 2019
 
Pharmacovigilance Risk Assessment Committee (PRAC) Meeting Highlights 13-16 May 2019

Pharmacovigilance Risk Assessment Committee (PRAC) Meeting Highlights 8-11 April 2019
 
Pharmacovigilance Risk Assessment Committee (PRAC) Meeting Highlights 12-15 March 2019
 
Pharmacovigilance Risk Assessment Committee (PRAC) Meeting Highlights 11-14 February 2019
 
Pharmacovigilance Risk Assessment Committee (PRAC) Meeting Highlights 14-17 January 2019

Meeting highlights from previous years




« Back